Vincorion (V1NC.DE) traded up 3.19 % during a 24 hours period ending at 09:02 PM Central Europe on Tuesday 27th. One Vincorion stock can currently be bought for about EUR 19.17 on popular exchanges. Current supply of Vincorion stocks is 48.7 mn. Vincorion has a current market capitalization of EUR 925 mn and approximately EUR 946.5 k worth of Vincorion was traded on exchanges in the last 24 hours. Since last month end, Vincorion has traded 9.9 % up. Simple moving average of last 200 days is at EUR 18.46. The highest price of past 52 weeks was recorded at EUR 23.9 on 05/07/2026. 52 weeks low was at EUR 15.3 on 04/15/2026.
Here is how related stocks have performed in the past 24 hours:
Thyssenkrupp Nucera & (NCH2.DE) traded up 4.55 % and now trades at EUR 7.87. Thyssenkrupp Nucera & has a market capitalisation of EUR 1 bn. On 28 October 2026, the former ThyssenKrupp materials division, now branded as TK‑Accelis Group AG & Co. KGaA, commenced trading on the Frankfurt Stock Exchange’s Prime Standard. The spin‑off was effected through a shareholder allocation that automatically assigned one TK‑Accelis share to every twenty ThyssenKrupp shares held, with the remaining 49 % distributed to existing shareholders. ThyssenKrupp retained a 51 % stake, preserving majority control while granting the new entity independent access to capital markets. The company, which employs roughly 15,500 staff and reported an annual turnover of about €11.4 billion in 2025, aims to lift its adjusted EBITDA margin to 4 – 5 % in the medium term, focusing on service‑center expansion, North American growth and operational efficiencies. Initial market reactions were mixed, with concerns about index inclusion and the company’s thin margin profile, but the move marks a significant step in ThyssenKrupp’s restructuring strategy.
Mbb (MBB.DE) traded up 0.49 % and now trades at EUR 203. Current market capitalisation for Mbb is EUR 1.1 bn. Current price/earnings ratio for Mbb is 17.21. MBB SE’s shares remained under pressure during Monday’s trading on the Frankfurt exchange, recording a modest decline of less than one percent. The company’s stock, which has been trading in the low‑200‑EUR range, was among the weaker performers in the SDAX, alongside a handful of other constituents that also saw modest drops. While the index itself advanced, MBB SE’s relative performance lagged behind the stronger names that lifted the SDAX, such as ATOSS Software and other technology‑focused companies. The market capitalisation of MBB SE is modest compared with the larger SDAX listings, and the stock’s trading volume is lower than that of the most active names in the index. Overall, MBB SE’s shares continued to face downward pressure amid the broader market’s moderate gains.
Immatics (4A3.F) traded down -0.59 % and now trades at EUR 6.34. Current market capitalisation for Immatics is EUR 1 bn. Immatics N.V. reported that its PRAME‑targeted bispecific, IMA402, has shown a favourable safety profile and encouraging antitumour activity in a phase‑1b study involving heavily pre‑treated patients with solid tumours, particularly melanoma and ovarian cancer. In the evaluated cohort of 40 patients who received the recommended phase‑2 dose range, the confirmed objective response rate was around one‑quarter, with a disease‑control rate exceeding 60 %. A complete response was observed in a melanoma patient, and several durable responses have lasted more than two years. The safety data indicate that most treatment‑related adverse events were mild or moderate, with transient lymphopenia and low‑grade cytokine release syndrome being the most common. The company plans to expand IMA402 into additional indications, including combination with checkpoint inhibitors and a forthcoming study of the related bispecific, IMA401, in lung cancer, with further data expected in 2027.
H&k (MLHK.PA) traded flat 0 % and now trades at EUR 30. H&k has a market capitalisation of EUR 1.1 bn. H&k has a current price to earnings ratio of 17.39.
Duerr (DUE.DE) traded up 2.4 % and now trades at EUR 16.12. Current market capitalisation for Duerr is EUR 1.1 bn. On 27 October 2026, Dürr Aktiengesellschaft announced a correction to a prior disclosure under German securities law, detailing changes in its voting‑right structure. The update, transmitted via the EQS News service, highlighted that UBS Group AG had acquired or increased holdings of shares and associated instruments, thereby affecting the distribution of voting rights. The notification specifies that the threshold for significant holdings was crossed on 21 October 2026, with new totals reflecting both direct share ownership and instrument‑based rights. The announcement clarifies that UBS Group AG does not exercise control over other entities holding interests in Dürr. No further corporate actions or financial performance details were included in the release, which serves primarily to inform shareholders and regulators of the updated voting‑right allocations.